Artykuł w czasopiśmie
Brak miniatury
Licencja
CC-BYCC-BY - Uznanie autorstwa
 

Safety of vaccines against SARS-CoV-2 among Polish patients with Multiple Sclerosis Treated with disease-modifying therapies

Uproszczony widok
dc.abstract.en(1) Background: The present study aims to report the side effects of vaccination against coronavirus disease 2019 (COVID-19) among patients with multiple sclerosis (MS) who were being treated with disease-modifying therapies (DMTs) in Poland. (2) Methods: The study included 2261 patients with MS who were being treated with DMTs, and who were vaccinated against COVID-19 in 16 Polish MS centers. The data collected were demographic information, specific MS characteristics, current DMTs, type of vaccine, side effects after vaccination, time of side-effect symptom onset and resolution, applied treatment, relapse occurrence, and incidence of COVID-19 after vaccination. The results were presented using maximum likelihood estimates of the odds ratio, t-test, Pearson’s chi-squared test, Fisher’s exact p, and logistic regression. The statistical analyses were performed using STATA 15 software. (3) Of the 2261 sampled patients, 1862 (82.4%) were vaccinated with nucleoside-modified messenger RNA (mRNA) vaccines. Mild symptoms after immunization, often after the first dose, were reported in 70.6% of individuals. Symptoms included arm pain (47.5% after the first dose and 38.7% after the second dose), fever/chills/flu-like symptoms (17.1% after the first dose and 20.5% after the second dose), and fatigue (10.3% after the first dose and 11.3% after the second dose). Only one individual presented with severe side effects (pro-thrombotic complications) after vaccination. None of the DMTs in the presented cohort were predisposed to the development of side effects. Nine patients (0.4%) had a SARS-CoV-2 infection confirmed despite vaccination. (4) Conclusions: Vaccination against SARS-CoV-2 is safe for people with MS who are being treated with DMTs. Most adverse events following vaccination are mild and the acute relapse incidence is low.
dc.affiliationUniwersytet Warszawski
dc.contributor.authorZajkowska, Olga
dc.contributor.authorKułakowska, Alina
dc.contributor.authorBrola, Waldemar
dc.contributor.authorZwiernik, Beata
dc.contributor.authorZwiernik, Jacek
dc.contributor.authorMilewska-Jędrzejczak, Marta
dc.contributor.authorZaborski, Jacek
dc.contributor.authorJasińska, Elżbieta
dc.contributor.authorZakrzewska-Pniewska, Beata
dc.contributor.authorNojszewska, Monika
dc.contributor.authorPodlecka-Piętowska, Aleksandra
dc.contributor.authorAdamczyk-Sowa, Monika
dc.contributor.authorMorawiec, Natalia
dc.contributor.authorNiedziela, Natalia
dc.contributor.authorKubicka-Bączyk, Katarzyna
dc.contributor.authorStolarz, Małgorzata
dc.contributor.authorBiałek, Marta
dc.contributor.authorKochanowicz, Jan
dc.contributor.authorKulikowska, Joanna
dc.contributor.authorMirończuk, Anna
dc.contributor.authorBazylewicz, Marcin
dc.contributor.authorChorąży, Monika
dc.contributor.authorKapica-Topczewska, Katarzyna
dc.contributor.authorPokryszko-Dragan, Ewa
dc.contributor.authorUbysz, Jakub
dc.contributor.authorChojdak-Łukasiewicz, Justyna
dc.contributor.authorKrzystanek, Ewa
dc.contributor.authorWalawska-Hrycek, Anna
dc.contributor.authorGalus, Weronika
dc.contributor.authorKalinowska-Łyszczarz, Alicja
dc.contributor.authorDyczkowska, Klara
dc.contributor.authorKania, Karolina
dc.contributor.authorStasiołek, Mariusz
dc.contributor.authorJurewicz, Anna
dc.contributor.authorWalczak, Agata
dc.contributor.authorCiach, Agnieszka
dc.contributor.authorSiger, Małgorzata
dc.contributor.authorŚwiderek-Matusiak, Mariola
dc.contributor.authorBartosik-Psujek, Halina
dc.contributor.authorPerenc, Adam
dc.contributor.authorRościszewska-Żukowska, Iwona
dc.contributor.authorPopiel, Małgorzata
dc.contributor.authorLech, Beata
dc.contributor.authorRejdak, Konrad
dc.contributor.authorJamroz-Wiśniewska, Anna
dc.contributor.authorSłowik, Agnieszka
dc.contributor.authorNowak, Klaudia
dc.contributor.authorMarona, Monika
dc.contributor.authorWnuk, Marcin
dc.contributor.authorTarasiuk, Joanna
dc.contributor.authorCzarnowska, Agata
dc.contributor.authorPOTEMKOWSKI, ANDRZEJ
dc.date.accessioned2024-01-25T19:34:41Z
dc.date.available2024-01-25T19:34:41Z
dc.date.copyright2022-05-12
dc.date.issued2022
dc.description.accesstimeAT_PUBLICATION
dc.description.financePublikacja bezkosztowa
dc.description.versionFINAL_PUBLISHED
dc.identifier.doi10.3390/VACCINES10050763
dc.identifier.issn2076-393X
dc.identifier.urihttps://repozytorium.uw.edu.pl//handle/item/118965
dc.identifier.weblinkhttps://mdpi-res.com/d_attachment/vaccines/vaccines-10-00763/article_deploy/vaccines-10-00763.pdf?version=1652332688
dc.languageeng
dc.pbn.affiliationeconomics and finance
dc.relation.ispartofVaccines
dc.rightsCC-BY
dc.sciencecloudnosend
dc.subject.enmultiple sclerosis
dc.subject.enSARS-CoV-2
dc.subject.envaccination
dc.subject.endisease-modifying therapies
dc.subject.enadverse event
dc.subject.plszczepionka
dc.subject.plSARS-CoV-2
dc.subject.plterapie modyfikujące przebieg choroby
dc.titleSafety of vaccines against SARS-CoV-2 among Polish patients with Multiple Sclerosis Treated with disease-modifying therapies
dc.typeJournalArticle
dspace.entity.typePublication